Fresenius Medical Care (FMC) has been given a "Neutral" rating by UBS, with a target price of 39 euros.
Analyst Graham Doyle has expressed concerns about the performance of the European medical technology sector, which has not performed as well as the overall market this year. Doyle's predictions for sales and earnings in 2025 are lower than the consensus estimates for 10 of the 17 sector stocks he covers, indicating a cautious outlook for the industry.
This analysis was published on November 26, 2024, highlighting the challenges faced by medical technology shares in the current market environment.